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With little understanding of how food, feed and fiber products are developed
and produced, and even less knowledge of the science of genetics, most
consumers are ill prepared to sift through the deluge of misinformation
bombarding them on a daily basis. Members of NABC have a unique oppor-
tunity to help set the record straight and challenge the myths that are circulated
by those who oppose, or question the use of, agricultural biotechnology.
Representatives of land-grant universities and other research institutes have
a deservedly high degree of credibility. Without being advocates, they can play a
vital role in educating the public, government officials, and the media, on basic
agricultural practices and scientific concepts that are critical to an objective
analysis of agricultural biotechnology.
Looking to the future, and in light of the rapid rate of adoption of crop
biotechnology and the diversity and complexity of products in the development
pipeline, I believe that product stewardship and regulation will play an
increasingly important role in promoting public confidence in the products of
biotechnology. Technology providers, growers, processors, and researchers all
have key roles to play in supporting strong governmental oversight of crop
biotechnology and implementing proactive product-stewardship programs.
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WHAT WE REALLY KNOW ABOUT THE SAFETY AND BENEFITS OF
BIOTECHNOLOGY CROPS
Six key arguments are commonly raised in opposition to the use of biotechnol-
ogy-derived crops. None of them withstand close scrutiny.
Myth #1: Lack of regulation—products are rushed to market with little or no
government oversight. The reality: unprecedented regulation of plants and plant
products. Products are reviewed by at least two federal agencies, the United
States Department of Agriculture (USDA) and the Food and Drug Administra-
tion (FDA) and often by three, i.e. including the Environmental Protection
Agency (EPA) (US, 2001) These reviews take place over a period of several
years while carefully controlled and monitored greenhouse and field tests are
conducted. All of this must occur before a product can ever enter the
marketplace. There is no comparable oversight for conventional hybrids and
cultivars. The jurisdiction of the regulatory agencies has been exercised since
1986 and universally recognized by regulated parties. The National Institutes of
Health (NIH) research guidelines have been followed since 1976 for laboratory
and greenhouse research.
Myth #2: No data. The reality: volumes of data. Health, safety and environmen-
tal data representing years of laboratory, greenhouse, and field research are
routinely submitted to and reviewed by the USDA, EPA, and FDA (NAS, 2000).
New data are requested by the agencies as needed.
Myth #3: No public participation. The reality: multiple public participation
opportunities. Multiple public participation opportunities have been provided
over the past 25 years by EPA, USDA and FDA, including via public meetings,
public comment on proposed rules and policies, agency web sites, scientific
peer review, and in response to published data.
Myth #4: No benefits. The reality: established benefits. Products have shown
clear agronomic, environmental, and health benefits, including high-oleic
soybean; slower ripening fruits and vegetables; improved protection from
insects and disease (reduced use of chemical insecticides and fungicides, fewer
acres cultivated, and less fuel, water, and fertilizer used); and improved
tolerance to herbicides (reduced need for chemical applications, promotion of
reduced tillage, control of soil erosion, and use of reduced-risk herbicides)
(Alliance, 2001; USDA, 2001).
Myth #5: Harm to health and environment. The reality: no evidence of actual
harm. With intensive governmental, academic, and commercial oversight for
the past 15 years, not a single instance of actual harm to health, safety, or the
environment has ever been confirmed for biotechnology crops on the market
today (EPA, 2000).
Myth #6: No labeling. The reality: health and safety labeling is required. Federal
labeling requirements are identical for all foods. Labeling solely for consumer
choice is not required by government in the United States (Federal Register,
1992, 2001).
KEY ISSUES IN PROMOTING PRODUCT STEWARDSHIP AND REGULATION
• To the producer of biotechnology-derived products and others in the chain
of commerce, government regulation provides assurance that appropriate
safety standards have been met in bringing a product to market. But even
the best efforts of regulators may prove inadequate, particularly when
dealing with a new technology, without the development and implementa-
tion of proactive product-stewardship programs.
• In its broadest terms, product stewardship can be thought of as the legal,
ethical and moral obligation to assess products and technologies to ensure
that they are safe as well as socially and environmentally responsible.
Stewardship includes the assessment—based on sound scientific
principles—of the potential impact of a particular product or technology
on human health and the environment, as well as those actions and
principles necessary to protect the integrity and viability of a particular
product or technology.
• Not all stewardship efforts are necessarily confined to individual
companies, nor should they be. Many activities are more appropriately
industry-wide responsibilities, which are necessary or appropriate for the
protection of products or technologies as a class. Many industries operate
on the basis of voluntary consensus standards, including a broad array of
standards developed by nationally and internationally recognized standard-
setting organizations. Government agencies routinely recognize such
standards, and federal law requires agencies to use technical standards that
are developed or adopted by voluntary consensus standards bodies, unless
it would be inconsistent with applicable law or otherwise impractical.
• From a legal perspective, the organizational unit responsible for oversight
of product stewardship must be empowered to ensure compliance with the
letter and spirit of applicable regulatory requirements and to prevent
potential product-related liabilities. Legal obligations in the United States
include the submission of applications, notifications, data, and information
in order to obtain the appropriate approvals and clearances from the
USDA, FDA and EPA under the Coordinated Framework for Regulation of
Biotechnology. Those obligations also extend to the post-market
surveillance of agricultural biotechnology and crop-derived products and
to compliance with appropriate reporting requirements, such as those
imposed by EPA for plant-incorporated protectants.
• In addition to biodiversity, examples of crop biotechnology stewardship
issues include: risk assessment and risk management plans; seed quality
and purity; protein safety, including potential for allergenicity; protein
levels in food and feed; insect-resistance-management plans for certain
plant-incorporated protectants; outcrossing and open pollination; identity
preservation, product channeling and trade.
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• A successful risk-management process should be a fundamental part of the
product-stewardship program, incorporated into each phase of product
development and commercialization. Key elements of the risk-management
process include: identifying every potential source of harm (hazard);
assessing the probability of occurrence of that harm (exposure); assessing
the risk, if any, resulting from the potential combination of hazard and
exposure; and the development of alternatives for the minimization and
management of the assessed risks.
• For products of agricultural biotechnology, the risks and risk-management
alternatives must be evaluated in the context of factors such as health,
safety, and environmental and agricultural impacts; regulatory acceptance;
public acceptance; market acceptance; and civil liability. Prior to
commercialization of any new plant-biotechnology product, the developer
would conduct a full, science-based risk assessment to identify and, to the
extent possible, quantify every risk presented. Each risk would be reviewed
in all relevant contexts and an appropriate management plan would be
established, including an effective strategy to mitigate any risk that
becomes a reality.
• Regulatory oversight and industry stewardship of crop-biotechnology
products, both pre-market and post-market, have occurred notwithstand-
ing the fact that new conventionally bred varieties of food, feed, and fiber
crops receive virtually no governmental oversight in the United States or
any other nation. Moreover, the National Academy of Sciences (NAS) has
repeatedly held—most recently in an April 2000 report on pest-protected
plants—that being a product of biotechnology does not make a plant
hazardous. Specifically, the NAS has found: (1) no evidence that unique
hazards exist either in the use of rDNA techniques or the movement of
genes between unrelated organisms; (2) that the risks associated with the
introduction of rDNA engineered organisms are the same in kind as those
associated with the introduction of unmodified organisms and organisms
modified by other methods; and (3) that assessment of the risks of
introducing rDNA-engineered organisms into the environment should be
based on the nature of the organism and the environment into which it is
introduced, not on the method by which it was produced.
• Rigorous, science-based safety assessments must be conducted for each
new product or product category, first by the product developers and then
by agency scientists. Conditions carefully tailored to address identified
risks should be placed on approvals where warranted, and approvals
should always be subject to review based on new data and information
from any credible source.
• It is the very nature of oversight of a rapidly developing technology that
regulation and stewardship must be dynamic processes, always subject to
reevaluation and modification based on new information and understand-
ing.
• Proactive product stewardship together with strong regulatory oversight
will be critical to the minimization of liability and, ultimately, to domestic
and global acceptance of products of modern biotechnology.
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